Acrivon Therapeutics Inc (NASDAQ:ACRV) shares, rose in value on Wednesday, June 18, with the stock price up by 2.48% to the previous day’s close as strong demand from buyers drove the stock to $1.24.
Actively observing the price movement in the last trading, the stock closed the session at $1.21, falling within a range of $1.2204 and $1.2965. The value of beta (5-year monthly) was 1.562. Referring to stock’s 52-week performance, its high was $10.16, and the low was $1.05. On the whole, ACRV has fluctuated by 5.08% over the past month.
With the market capitalization of Acrivon Therapeutics Inc currently standing at about $38.88 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-14.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ACRV’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ACRV currently trading nearly 3.81% and -9.48% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.20, while the 7-day volatility ratio is showing 3.66% which for the 30-day chart, stands at 4.29%. Furthermore, Acrivon Therapeutics Inc (ACRV)’s beta value is 1.56, and its average true range (ATR) is 0.11.
A comparison of Acrivon Therapeutics Inc (ACRV) with its peers suggests the former has fared considerably weaker in the market. ACRV showed an intraday change of 2.48% in last session, and over the past year, it shrunk by -82.90%%.
Data on historical trading for Acrivon Therapeutics Inc (NASDAQ:ACRV) indicates that the trading volumes over the past 10 days have averaged 0.4 and over the past 3 months, they’ve averaged 773.02K. According to company’s latest data on outstanding shares, there are 31.35 million shares outstanding.
Nearly 29.34% of Acrivon Therapeutics Inc’s shares belong to company insiders and institutional investors own 56.77% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.05 million shares as on 2025-05-30, resulting in a short ratio of 1.4. According to the data, the short interest in Acrivon Therapeutics Inc (ACRV) stood at 891.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 1.39 million. The stock has fallen by -79.40% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ACRV stock heading into the next quarter.
